Medicines
We market medicines that are designed to improve the health and quality of life of patients in the UK – medicines which are innovative and effective.
The content on this page is intended for members of the public.
Qtern®▼ (dapagliflozin/saxagliptin)
Symbicort® (budesonide/formoterol)
Tenoret 50® (atenolol/chlorthalidone)
Tenoretic® (atenolol/chlorthalidone)
Vimovo® (naproxen/esomeprazole magnesium)
Xigduo®▼ (dapagliflozin/metformin)
Zestoretic® (lisinopril dehydrate/hydrochlorothiazide)
Other resources
Sharing clinical trials information
We publish information about the registration and results of all new and ongoing clinical trials for all products in all phases on our dedicated website.
Interested in a career with AstraZeneca
At AstraZeneca we share a common purpose: to push the boundaries of science to deliver life-changing medicines. Please visit our careers site to find more information.
Report an adverse event
All pharmacologically effective drugs have benefits and risks. The risk may be insignificant or may be acceptable in relation to the drug's therapeutic action. Continuous monitoring of the safety of a drug throughout the duration of its use helps to ensure that its risks and benefits remain acceptable. AstraZeneca is committed to protecting the safety of patients who receive our products. All adverse events should be reported to AstraZeneca by freephone +44 (0) 1582 836836.
VVPM ID: GB-7358
Date of Preparation: June 2017